MedTrace Logo

PET and MRI Brain Imaging of Bipolar Disorder

NCT01880957 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2022-07-20

Study results available
· View outcomes & findings →

Summary

The primary aims of this study are to:

1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE).
2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT.
3. Assess the effect of lithium treatment of bipolar disorder on 5-HT1A BP.
4. Assess the effect of lamotrigine treatment of bipolar disorder on 5-HTT and 5-HT1A BP.
5. Assess the effect of lithium treatment of unipolar depression on 5-HTT BP.

Conditions

Interventions

DRUG

Lithium

DRUG

Lamotrigine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • The Dana Foundation

    collaborator OTHER

  • Stony Brook University

    lead OTHER

Principal Investigators

  • Ramin Parsey, MD, PhD · Stony Brook University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-08
Primary Completion
2017-06-23
Completion
2017-06-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01880957 on ClinicalTrials.gov